Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Can metabolomic profiling predict response to therapy?

Shifts in cellular metabolism are central to activation, differentiation and proliferation of inflammatory cells and can contribute to the pathogenesis of inflammatory diseases. Integrating metabolomics data with other omics data is a major challenge but might enable clinicians to stratify stages of disease and response to therapy in patients with rheumatoid arthritis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Ajeganova, S. & Huizinga, T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther. Adv. Musculoskelet. Dis. 9, 249–262 (2017).

    CAS  Article  Google Scholar 

  2. 2.

    Teitsma, X. M. et al. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. Arthritis Res. Ther. 20, 230 (2018).

    Article  Google Scholar 

  3. 3.

    DeBerardinis, R. J. & Thompson, C. B. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148, 1132–1144 (2012).

    CAS  Article  Google Scholar 

  4. 4.

    Bijlsma, J. W. J. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388, 343–355 (2016).

    CAS  Article  Google Scholar 

  5. 5.

    Kanarek, N. et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature 559, 632–636 (2018).

    CAS  Article  Google Scholar 

  6. 6.

    Teitsma, X. M. et al. Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy. Arthritis Res. Ther. 19, 10 (2017).

    Article  Google Scholar 

  7. 7.

    Teitsma, X. M. et al. Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis. Ann. Rheum. Dis. (2018).

    Article  PubMed  Google Scholar 

  8. 8.

    Wang, J. et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open 3, e003199 (2013).

    Article  Google Scholar 

  9. 9.

    Kapoor, S. R. et al. Metabolic profiling predicts response to anti-TNFα therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 65, 1448–1456 (2013).

    CAS  Article  Google Scholar 

  10. 10.

    Young, S. P. et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheumatol. 65, 2015–2023 (2013).

    CAS  Article  Google Scholar 

Download references


C. M. M. is funded by a Research Fellowship from the National Institute for Health Research.

Author information



Corresponding author

Correspondence to Stephen P. Young.

Ethics declarations

Competing interests

C. M. M. declares that she has received honoraria from Pfizer. S.P.Y. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

McGrath, C.M., Young, S.P. Can metabolomic profiling predict response to therapy?. Nat Rev Rheumatol 15, 129–130 (2019).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing